Abstract: 2,3,5-trimethyl-benzoquinone is produced by oxidizing 2,3,6-trimethyl-phenol in the presence of a catalyst of cupric chloride and lithium chloride in a solvent mixture of an aromatic hydrocarbon and a lower aliphatic alcohol having 1 to 4 carbon atoms.

Abstract: A novel compound, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, and a salt thereof are disclosed together with a number of different processes for the preparation of the compound. The uses of the novel compound as an agent for treating papillomata are also disclosed.

Abstract: Skin diseases with keratinization and allergic or inflammatory skin diseases are treated by orally or parenterally administering to an adult human patient from 40 mg to 4 g/day of a polyprenyl compound having the formula (I): ##STR1## in which each of n and m is 0, 1, or 2, n+m is 0, 1 or 2, A is ##STR2## and B is ##STR3## [in which R represents the hydroxyl group, a lower alkoxy group, or ##STR4## (wherein each of R.sub.1 and R.sub.

Abstract: A novel compound, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, and a salt thereof are disclosed together with a number of different processes for the preparation of the compound. The uses of the novel compound as an anticancer agent are also disclosed.

Abstract: An anti-cancer agent which comprises a polyprenvl compound having the formula (I): ##STR1## in which each of n and m is 0, 1 or 2, n+m is 0, 1 or 2, A is ##STR2## and B is ##STR3## in which R represents the hydroxyl group, a lower alkoxy group, or ##STR4## (wherein each of R.sub.1 and R.sub.

Abstract: Non-steroidal, anti-inflammatory drugs are disclosed which are polyprenyl alcohol esters of indolyl lower carboxylic acids, phenyl lower carboxylic acids, acetyl salicyclic acid, anthranilic acid and derivatives thereof.

Abstract: A conjugated polyprenylcarboxylic acid and its derivative having the formula: ##STR1## in which each of n and m is 0, 1 or 2, n+m is 1 or 2, A is ##STR2## and R is the hydroxyl group, a lower alkoxy group or ##STR3## wherein each of R.sub.1 and R.sub.2 represents the hydrogen atom, a lower alkyl group, or an aryl group; provided that R is ##STR4## if A is ##STR5## n is 1 and m is 0.

Abstract: This invention relates to polyprenylcarboxylic acid amides represented by the following general formula (I): ##STR1## wherein n is an integer of from 1 to 4, a and b stand for hydrogen atoms or a direct valence bond between the carbon atoms to which a and b are attached, c and d stand for hydrogen atoms or a direct valence bond between the carbon atoms to which c and d are attached, and R.sub.1 and R.sub.2 stand for a hydrogen atom, a lower alkyl group, a phenyl group which may be substituted or an aralkyl group which may be substituted, or R.sub.1 and R.sub.2 form, together with the adjacent nitrogen atom, a 5- or 6-membered heterocyclic ring which may contain other hetero atoms or may be substituted,and also to a process for the preparation of said polyprenylcarboxylic acid amide and to a pharmaceutical composition for treating liver dysfunction comprising said polyprenylcarboxylic acid amide.

Abstract: Non-steroidal, anti-inflammatory drugs are disclosed which are polyprenyl alcohol esters of indolyl lower carboxylic acids, phenyl lower carboxylic acids, acetyl salicylic acid, anthranilic acid and derivatives thereof.

Abstract: An .alpha.,.beta.-dihydropolyprenyl derivative having the formula (I): ##STR1## wherein X represents a group of --COOR.sub.1 or --CH.sub.2 OR.sub.2 in which R.sub.1 is the hydrogen atom or an alkyl group having one to four carbon atoms and R.sub.2 is the hydrogen atom or an aliphatic acyl group having one to four carbon atoms; and n is an integer of one to four. A process for the preparation of the .alpha.,.beta.-dihydropolyprenyl derivative and a therapeutic agent for treatment of liver diseases comprising the same are also disclosed.

Abstract: Polyprenyl carboxylic acid derivatives having the general formula (I): ##STR1## in which n is an integer of from 2 to 4, R.sub.1 represents the hydrogen atom or a protecting group for the carboxylic acid group, and R.sub.2 represents a hydroxymethyl, formyl or carboxyl group, are disclosed. A process for the preparation of the polyprenyl carboxylic acid derivative involving microbiological oxidation using a strain belonging to the genus Nocardia is disclosed. The compounds have anti-ulcer activity and hypotensive activity. The compounds also are useful as intermediates for preparing polyprenyl carboxylic acids of the formula ##STR2## and esters thereof, wherein l is an integer of from 4 to 11. The polyprenyl carboxylic acids and esters thereof have hypotensive activity and anti-ulcer activity.

Abstract: The polyprenyl compound having the formula: ##STR1## wherein X represents a group of the formula: --CH.dbd.CH--, a group of the formula: ##STR2## or a group of the formula: ##STR3## and Y represents a group of the formula: --COOR.sup.1 in which R.sup.1 represents a hydrogen atom or a lower alkyl group or a group of the formula: ##STR4## in which R.sup.2 represents a hydrogen atom or a lower alkyl group, is new and useful as a medicine.

Abstract: An .alpha.,.beta.-dihydropolyprenyl derivative having the formula (I): ##STR1## wherein X represents a group of --COOR.sub.1 or --CH.sub.2 OR.sub.2 in which R.sub.1 is the hydrogen atom or a lower alkyl group and R.sub.2 is the hydrogen atom or an aliphatic acyl group having one to four carbon atoms; and n is an integer of one to four. A process for the preparation of the .alpha.,.beta.-dihydropolyprenyl derivative and a therapeutic agent for treatment of liver diseases comprising the same are also disclosed.

Abstract: A process is disclosed for the preparation of a compound having the general formula: ##STR1## wherein n is an integer of from 2 to 4, R.sub.1 is an ester-forming moiety effective as a protecting group for a carboxyl group, and R.sub.2 is hydroxymethyl, formyl or carboxyl. The compounds (I) are useful as intermediates for the preparation of polyprenyl compounds having hypotensive and anti-ulcer activity. The process of the invention includes cultivating a microorganism selected from a strain of the genus Nocardia called BPM 1613, FERM-P No. 1609, Corynebacterium equi IAM 1038, Candida lipolytica IFO 0746, and Mycobacterium smegmatis IFO 3083, in a nutritive culture medium, in the presence of a compound having the general formula: ##STR2## wherein R.sub.3 is an ester-forming moiety effective as a protecting group for a carboxyl group, whereby the microorganism utilizes the compound (II) as a carbon source and oxidizes the compound (II), thereby converting the compound (II) into the compound (I).

Abstract: Polyprenyl carboxylic acid amides of the formula ##STR1## process for their preparation and use thereof for treating liver dysfunction are disclosed.

Abstract: Non-steroidal, anti-inflammatory drugs are disclosed which are polyprenyl alcohol esters of indolyl lower carboxylic acids, phenyl lower carboxylic acids, acetyl salicylic acid, anthranilic acid and derivatives thereof.

Abstract: Phosphoramide derivatives of the general formula: ##STR1## are disclosed wherein X and Y each represents a hydrogen atom or X and Y are removed to form a double bond between the respective adjoining carbon atoms, and n represents an integer of 0 to 2. A process for the preparation of these compounds and pharmaceutical compositions containing these phosphoramide derivatives are also disclosed. The phosphoramide derivatives of the invention are used to treat urethral calculosis and pyelonephritis.

Abstract: 6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ols of the general formula: ##STR1##

Abstract: A compound, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, and a salt thereof are disclosed as a therapeutic agent for treatment of skin diseases with keratinization.

Abstract: .beta., .gamma.-Dihydropolyprenyl alcohols of the general formula: ##STR1## wherein n represents an integer of 8 to 10, exhibit hypotensive activity and anti-hepatic disease-activity.